DS-1211
/ Daiichi Sankyo
- LARVOL DELTA
Home
Next
Prev
1 to 8
Of
8
Go to page
1
June 14, 2024
A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum
(clinicaltrials.gov)
- P2 | N=64 | Completed | Sponsor: Daiichi Sankyo | Active, not recruiting ➔ Completed | Trial completion date: Apr 2024 ➔ Nov 2023 | Trial primary completion date: Apr 2024 ➔ Nov 2023
Trial completion • Trial completion date • Trial primary completion date
October 03, 2023
A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum
(clinicaltrials.gov)
- P2 | N=65 | Active, not recruiting | Sponsor: Daiichi Sankyo, Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Sep 2023 ➔ Apr 2024 | Trial primary completion date: Aug 2023 ➔ Apr 2024
Enrollment closed • Trial completion date • Trial primary completion date
November 20, 2022
Anticalcification effects of DS-1211 in pseudoxanthoma elasticum mouse models and the role of tissue-nonspecific alkaline phosphatase in ABCC6-deficient ectopic calcification.
(PubMed, Sci Rep)
- "TNAP plays an active role in pathomechanistic pathways of dysregulated calcification, demonstrated by reduced ectopic calcification in mice with lower TNAP activity. DS-1211 may be a potential therapeutic drug for PXE."
Journal • Preclinical • ABCC6
November 04, 2022
A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum
(clinicaltrials.gov)
- P2 | N=64 | Recruiting | Sponsor: Daiichi Sankyo, Inc. | Not yet recruiting ➔ Recruiting
Enrollment open
October 06, 2022
A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum
(clinicaltrials.gov)
- P2 | N=64 | Not yet recruiting | Sponsor: Daiichi Sankyo, Inc.
New P2 trial
September 03, 2022
In vitro and in vivo pharmacological profiles of DS-1211, a novel potent, selective, and orally bioavailable tissue-nonspecific alkaline phosphatase inhibitor.
(PubMed, J Bone Miner Res)
- "Overall, in vitro and in vivo studies showed DS-1211 is a potent and selective TNAP inhibitor across species. Further in vivo pharmacology studies in ectopic calcification animal models and clinical investigations of DS-1211 in patient populations are warranted."
Journal • Preclinical
August 09, 2022
A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum
(clinicaltrialsregister.eu)
- P2 | N=64 | Ongoing | Sponsor: Clinical Director, Daiichi Sankyo, Inc.
New P2 trial
January 13, 2022
Phase I studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of DS-1211, a tissue-nonspecific alkaline phosphatase inhibitor.
(PubMed, Clin Transl Sci)
- "Post-treatment PD assessments were consistent with exposure-dependent TNAP inhibition. These data support further evaluation of DS-1211 for ectopic calcification diseases."
Clinical • Journal • P1 data • PK/PD data
1 to 8
Of
8
Go to page
1